Results 241 to 250 of about 219,440 (288)

Latviešu Ārstu un Zobārstu Apvienības goda biedra profesora Dr. med. Jēkaba Alkšņa dzīves gaita

Acta Medico-Historica Rigensia, 1999
AML Medicīnas vēstures institūts
doaj   +1 more source

SAB – a promising new treatment to improve remission rates in AML in the elderly?

, 2002
Keith Wheatley
openalex   +1 more source

The role of blinatumomab in adult acute B lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Blinatumomab, a CD19‐directed bispecific T‐cell engager, has become a crucial part of BCP‐ALL therapy in r/r disease, MRD‐positive disease and has recently been implemented into first‐line therapy of BCP‐ALL. This review discusses important clinical trials with a focus on blinatumomab in first‐line therapy of adult BCP‐ALL.
Anne C. Wilke, Nicola Gökbuget
wiley   +1 more source

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)

, 2002
Louise Kelly, Jin‐Chen Yu, Christina Boulton, Mutiah Apatira, Jason Li, Carol M. Sullivan, Ifor R. Williams, Sonia M Amaral, David P. Curley, Nicole Duclos, Donna Neuberg, Robert M. Scarborough, Anjali Pandey, Stanley J. Hollenbach, Keith Abe, Nathalie A. Lokker, D. Gary Gilliland, Neill A. Giese   +17 more
openalex   +1 more source

Mapping VEXAS‐associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population

British Journal of Haematology, EarlyView.
VEXAS syndrome is a late‐onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK cohorts estimates the incidence of VEXAS to be 1.51/100 000, or 171 new cases in the population of men over the age of 50 who are being investigated for myeloid
Ana Martinez Rodriguez, Leon Chang, Dorota Rowczenio, Alexandra Smith, Ebun Omoyinmi, James A. Poulter, Andrew McGregor, Sebastian Francis, Roochi Trikha, Adam Al‐Hakim, Kar Lok Kong, David G. Kent, Helen Lachmann, Austin Kulasekararaj, Catherine Cargo, Sinisa Savic   +15 more
wiley   +1 more source

Comparability of external and internal control patients for the prospective randomized HOVON‐103 trial in older AML patients

British Journal of Haematology, EarlyView.
Summary Real‐world data (RWD) previously contributed to post‐marketing regulatory decision‐making, but are currently also considered as external controls to single‐arm trials. The use of RWD control data may be compromised by methodological issues, urging validation of RWD control cohorts.
Sjoerd J. F. Hermans, Jurjen Versluis, Erik D. van Werkhoven, Yvette van Norden, Jeroen J. W. M. Janssen, Gerwin A. Huls, Thomas Pabst, Dimitri A. Breems, Elizabeth Berkx, Avinash G. Dinmohamed, Peter C. Huijgens, Eric Sträng, Jesús María Hernández Rivas, Marta Sobas, Rosa Ayala Diaz, Joaquin Martinez Lopez, Klaus H. Metzeler, Torsten Haferlach, Christian Thiede, Carin A. Uyl‐de Groot, Lars Bullinger, Bob Löwenberg, Gert J. Ossenkoppele, Francesco Pignatti, Jan J. Cornelissen   +24 more
wiley   +1 more source

Real‐world clinical experience with NGS‐based chimerism analyses in haematopoietic stem cell transplant patients

British Journal of Haematology, EarlyView.
This study demonstrates the clinical utility of a next‐generation sequencing (NGS)‐based chimerism assay (CASAL) in haematopoietic stem cell transplantation (HSCT). Compared to conventional short tandem repeat (STR) methods, CASAL showed significantly higher marker informativeness, detecting mixed chimerism (MC) below 5% recipient DNA with a median of ...
Jin Ju Kim, Soon Sung Kwon, Yu Jeong Choi, Yehyun Kang, Yu Jin Park, Saeam Shin, Seung‐Tae Lee, Jong Rak Choi   +7 more
wiley   +1 more source

Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1

British Journal of Haematology, EarlyView.
Summary Acute myeloid leukaemia (AML) is a severe disease occurring mainly in the elderly population. Venetoclax (VEN) combined with azacitidine has changed the paradigm of treatment of AML. Nevertheless, approximately 30% of patients are primary refractory to VEN (VEN‐R), with no current therapeutic option.
Sylvain Garciaz, Camille Montersino, Maxence Bourgoin, Arnaud Jacquel, Rémy Castellano, Arnaud Guille, Max Chaffanet, François Bertucci, Marie‐Anne Hospital, José Adélaïde, Patrick Auberger, Norbert Vey, Yves Collette   +12 more
wiley   +1 more source

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies

British Journal of Haematology, EarlyView.
A retrospective analysis of patients with chronic myelomonocytic leukaemia treated with oral decitabine 35 mg + cedazuridine 100 mg suggested favourable outcomes, particularly in higher risk patients. The results provide a rationale for further prospective study of oral decitabine/cedazuridine to identify subgroups of this population who would benefit ...
Michael R. Savona, Olatoyosi Odenike, Gail J. Roboz, Harshad Amin, Amy E. DeZern, Elizabeth A. Griffiths, Kim‐Hien Dao, Amer M. Zeidan, Bhavana Bhatnagar, Rena Buckstein, Brian Leber, Mary‐Margaret Keating, Somedeb Ball, Aram Oganesian, Yuri Sano, Harold N. Keer, Guillermo Garcia‐Manero   +16 more
wiley   +1 more source

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013–2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy

British Journal of Haematology, EarlyView.
Three‐year overall survival (OS) and leukaemia‐free survival (LFS) rates were 28.5% and 24.4% in allogeneic haematopoietic cell transplantation (HCT) for primary refractory acute myeloid leukaemia from 2013 to 2022 in Japan. Age ≥ 50 years, performance status ≥2, adverse cytogenetics, extramedullary disease at diagnosis and peripheral blood blasts at ...
Takaaki Konuma, Yoshimitsu Shimomura, Shohei Mizuno, Satoshi Yamasaki, Shunsuke Yui, Naoyuki Uchida, Noriko Doki, Masatsugu Tanaka, Satoshi Yoshihara, Tetsuya Eto, Yuta Katayama, Yuna Katsuoka, Masahito Tokunaga, Shuichi Ota, Mamiko Sakata‐Yanagimoto, Kazuya Ishiwata, Yoshinobu Kanda, Toshiro Kawakita, Makoto Onizuka, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Masamitsu Yanada   +22 more
wiley   +1 more source